The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2015

Filed:

Jun. 22, 2012
Applicants:

Youyi Peng, New York, NY (US);

Lawrence P. Wennogle, New York, NY (US);

Qiang Zhang, New York, NY (US);

John Tomesch, New York, NY (US);

Inventors:

Youyi Peng, New York, NY (US);

Lawrence P. Wennogle, New York, NY (US);

Qiang Zhang, New York, NY (US);

John Tomesch, New York, NY (US);

Assignee:

INTRA-CELLULAR THERAPIES, INC., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); C07D 401/12 (2006.01); A61K 31/454 (2006.01); A61K 45/06 (2006.01); A61K 31/4745 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01);
Abstract

It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.


Find Patent Forward Citations

Loading…